<DOC>
	<DOCNO>NCT00603499</DOCNO>
	<brief_summary>Objective : test BP lowering-effect oral magnesium supplementation , magnesium chloride ( MgCl2 ) solution , 2.5 g daily , uncomplicated hypertensive type 2 diabetic subject decrease serum magnesium level Design : Randomised double blind placebo control trial . Setting : Outpatients type 2 diabetes Durango , city northern Mexico Subjects : 82 subject 40 75 year age type 2 diabetes serum magnesium deficiency uncomplicated hypertension . Interventions : During 4 month intervention group receive 2.5 gr magnesium chloride ( 50 ml solution contain 50 gr MgCl2 1000 ml solution ) . Controls receive inert placebo . Main outcome measure : Change blood pressure . Increase serum magnesium Secondary outcomes measure : Changes lipid profile</brief_summary>
	<brief_title>Magnesium Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Type 2 diabetes Decreased serum magnesium level Uncomplicated hypertension 40 75 year age Men Women Chronic diarrhea Alcohol intake ( equal 30 g per day ) Use diuretic and/or calcium antagonist drug Previous oral magnesium supplementation Ischemic diseases ; AND Reduced renal function</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Hypomagnesemia</keyword>
</DOC>